264 related articles for article (PubMed ID: 30612311)
1. Sensitization of colorectal cancer to irinotecan therapy by PARP inhibitor rucaparib.
Augustine T; Maitra R; Zhang J; Nayak J; Goel S
Invest New Drugs; 2019 Oct; 37(5):948-960. PubMed ID: 30612311
[TBL] [Abstract][Full Text] [Related]
2. The use of Olaparib (AZD2281) potentiates SN-38 cytotoxicity in colon cancer cells by indirect inhibition of Rad51-mediated repair of DNA double-strand breaks.
Tahara M; Inoue T; Sato F; Miyakura Y; Horie H; Yasuda Y; Fujii H; Kotake K; Sugano K
Mol Cancer Ther; 2014 May; 13(5):1170-80. PubMed ID: 24577941
[TBL] [Abstract][Full Text] [Related]
3. The poly (ADP-ribose) polymerase inhibitor rucaparib suppresses proliferation and serves as an effective radiosensitizer in cervical cancer.
Tang M; Liu Q; Zhou L; Chen L; Yang X; Yu J; Wang Y; Qiu H
Invest New Drugs; 2019 Feb; 37(1):65-75. PubMed ID: 29872938
[TBL] [Abstract][Full Text] [Related]
4. Histone deacetylase inhibitor, suberoylanilide hydroxamic acid (SAHA), enhances anti-tumor effects of the poly (ADP-ribose) polymerase (PARP) inhibitor olaparib in triple-negative breast cancer cells.
Min A; Im SA; Kim DK; Song SH; Kim HJ; Lee KH; Kim TY; Han SW; Oh DY; Kim TY; O'Connor MJ; Bang YJ
Breast Cancer Res; 2015 Mar; 17():33. PubMed ID: 25888415
[TBL] [Abstract][Full Text] [Related]
5. Synergistic interaction between the EGFR tyrosine kinase inhibitor gefitinib ("Iressa") and the DNA topoisomerase I inhibitor CPT-11 (irinotecan) in human colorectal cancer cells.
Koizumi F; Kanzawa F; Ueda Y; Koh Y; Tsukiyama S; Taguchi F; Tamura T; Saijo N; Nishio K
Int J Cancer; 2004 Jan; 108(3):464-72. PubMed ID: 14648715
[TBL] [Abstract][Full Text] [Related]
6. Phase II Study of Olaparib (AZD-2281) After Standard Systemic Therapies for Disseminated Colorectal Cancer.
Leichman L; Groshen S; O'Neil BH; Messersmith W; Berlin J; Chan E; Leichman CG; Cohen SJ; Cohen D; Lenz HJ; Gold P; Boman B; Fielding A; Locker G; Cason RC; Hamilton SR; Hochster HS
Oncologist; 2016 Feb; 21(2):172-7. PubMed ID: 26786262
[TBL] [Abstract][Full Text] [Related]
7. Poly (ADP-ribose) polymerase inhibition enhances trastuzumab antitumour activity in HER2 overexpressing breast cancer.
García-Parra J; Dalmases A; Morancho B; Arpí O; Menendez S; Sabbaghi M; Zazo S; Chamizo C; Madoz J; Eroles P; Servitja S; Tusquets I; Yelamos J; Lluch A; Arribas J; Rojo F; Rovira A; Albanell J
Eur J Cancer; 2014 Oct; 50(15):2725-34. PubMed ID: 25128455
[TBL] [Abstract][Full Text] [Related]
8. Preferential potentiation of topoisomerase I poison cytotoxicity by PARP inhibition in S phase.
Znojek P; Willmore E; Curtin NJ
Br J Cancer; 2014 Sep; 111(7):1319-26. PubMed ID: 25003660
[TBL] [Abstract][Full Text] [Related]
9. The Combination of the PARP Inhibitor Rucaparib and 5FU Is an Effective Strategy for Treating Acute Leukemias.
Falzacappa MV; Ronchini C; Faretta M; Iacobucci I; Di Rorà AG; Martinelli G; Meyer LH; Debatin KM; Orecchioni S; Bertolini F; Pelicci PG
Mol Cancer Ther; 2015 Apr; 14(4):889-98. PubMed ID: 25667168
[TBL] [Abstract][Full Text] [Related]
10. Enhanced anti-colorectal cancer effects of carfilzomib combined with CPT-11 via downregulation of nuclear factor-κB in vitro and in vivo.
Tang W; Su G; Li J; Liao J; Chen S; Huang C; Liu F; Chen Q; Ye Y
Int J Oncol; 2014 Sep; 45(3):995-1010. PubMed ID: 24968890
[TBL] [Abstract][Full Text] [Related]
11. Co-targeting poly(ADP-ribose) polymerase (PARP) and histone deacetylase (HDAC) in triple-negative breast cancer: Higher synergism in BRCA mutated cells.
Marijon H; Lee DH; Ding L; Sun H; Gery S; de Gramont A; Koeffler HP
Biomed Pharmacother; 2018 Mar; 99():543-551. PubMed ID: 29902865
[TBL] [Abstract][Full Text] [Related]
12. The PARP inhibitor ABT-888 synergizes irinotecan treatment of colon cancer cell lines.
Davidson D; Wang Y; Aloyz R; Panasci L
Invest New Drugs; 2013 Apr; 31(2):461-8. PubMed ID: 23054213
[TBL] [Abstract][Full Text] [Related]
13. The selective poly(ADP-ribose) polymerase-1(2) inhibitor, CEP-8983, increases the sensitivity of chemoresistant tumor cells to temozolomide and irinotecan but does not potentiate myelotoxicity.
Miknyoczki S; Chang H; Grobelny J; Pritchard S; Worrell C; McGann N; Ator M; Husten J; Deibold J; Hudkins R; Zulli A; Parchment R; Ruggeri B
Mol Cancer Ther; 2007 Aug; 6(8):2290-302. PubMed ID: 17699724
[TBL] [Abstract][Full Text] [Related]
14. Rad51 Degradation: Role in Oncolytic Virus-Poly(ADP-Ribose) Polymerase Inhibitor Combination Therapy in Glioblastoma.
Ning J; Wakimoto H; Peters C; Martuza RL; Rabkin SD
J Natl Cancer Inst; 2017 Mar; 109(3):1-13. PubMed ID: 28376211
[TBL] [Abstract][Full Text] [Related]
15. Activity of trabectedin and the PARP inhibitor rucaparib in soft-tissue sarcomas.
Laroche A; Chaire V; Le Loarer F; Algéo MP; Rey C; Tran K; Lucchesi C; Italiano A
J Hematol Oncol; 2017 Apr; 10(1):84. PubMed ID: 28399901
[TBL] [Abstract][Full Text] [Related]
16. Vulnerability to low-dose combination of irinotecan and niraparib in ATM-mutated colorectal cancer.
Vitiello PP; Martini G; Mele L; Giunta EF; De Falco V; Ciardiello D; Belli V; Cardone C; Matrone N; Poliero L; Tirino V; Napolitano S; Della Corte C; Selvaggi F; Papaccio G; Troiani T; Morgillo F; Desiderio V; Ciardiello F; Martinelli E
J Exp Clin Cancer Res; 2021 Jan; 40(1):15. PubMed ID: 33407715
[TBL] [Abstract][Full Text] [Related]
17. MRE11 deficiency increases sensitivity to poly(ADP-ribose) polymerase inhibition in microsatellite unstable colorectal cancers.
Vilar E; Bartnik CM; Stenzel SL; Raskin L; Ahn J; Moreno V; Mukherjee B; Iniesta MD; Morgan MA; Rennert G; Gruber SB
Cancer Res; 2011 Apr; 71(7):2632-42. PubMed ID: 21300766
[TBL] [Abstract][Full Text] [Related]
18. Oncolytic reovirus preferentially induces apoptosis in KRAS mutant colorectal cancer cells, and synergizes with irinotecan.
Maitra R; Seetharam R; Tesfa L; Augustine TA; Klampfer L; Coffey MC; Mariadason JM; Goel S
Oncotarget; 2014 May; 5(9):2807-19. PubMed ID: 24798549
[TBL] [Abstract][Full Text] [Related]
19. Epigenetic mechanisms of irinotecan sensitivity in colorectal cancer cell lines.
Crea F; Giovannetti E; Cortesi F; Mey V; Nannizzi S; Gallegos Ruiz MI; Ricciardi S; Del Tacca M; Peters GJ; Danesi R
Mol Cancer Ther; 2009 Jul; 8(7):1964-73. PubMed ID: 19531575
[TBL] [Abstract][Full Text] [Related]
20. Poly(ADP-ribose)polymerase (PARP) inhibition and anticancer activity of simmiparib, a new inhibitor undergoing clinical trials.
Yuan B; Ye N; Song SS; Wang YT; Song Z; Chen HD; Chen CH; Huan XJ; Wang YQ; Su Y; Shen YY; Sun YM; Yang XY; Chen Y; Guo SY; Gan Y; Gao ZW; Chen XY; Ding J; He JX; Zhang A; Miao ZH
Cancer Lett; 2017 Feb; 386():47-56. PubMed ID: 27847302
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
